Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
Prediction markets Kalshi and Polymarket are facing criticism for allowing bets on clinical trial outcomes, with researchers warning that such betting could encourage insider trading and compromise drug development processes. While the platforms argue that these markets provide useful information to patients, the ethical concerns raised highlight potential conflicts between financial incentives and scientific integrity in medical research.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- NPRTrace: Left
Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
Prediction markets Kalshi and Polymarket are facing criticism for allowing bets on clinical trial outcomes, with researchers warning that such betting could encourage insider trading and compromise drug development processes. While the platforms argue that these markets provide useful information to patients, the ethical concerns raised highlight potential conflicts between financial incentives and scientific integrity in medical research.
Rate outletRead original
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
Comments
0No comments yet. Say what you noticed in the coverage.
Trending